Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 660

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States

Open access
Marrero, Jorge A., Fontana, Robert J., Su, Grace L., Conjeevaram, Hari S., Emick, Dawn M., Lok, Anna S.·2002·Hepatology

Abstract

The incidence of hepatocellular carcinoma (HCC) in the United States is increasing, but the clinical characteristics of American patients with HCC have not been well described. The aims of this study were to determine the etiology of liver disease and short-term outcome among HCC patients presenting to a single center in the United States. One hundred five consecutive patients with HCC were studied; mean age was 59 years, 67% were men, and 76% were non-Hispanic white. The most common etiology of liver disease was hepatitis C (51%) and cryptogenic cirrhosis (29%). Half of the patients with cryptogenic cirrhosis had histologic or clinical features associated with nonalcoholic fatty liver disease (NAFLD). Fifty-three (50%) patients had HCC detected during surveillance (group I), whereas the remaining patients had symptomatic tumors (group II). Group I patients had smaller tumors (P = 0.01), were more likely to be eligible for surgical treatment (P = 0.005), and had a better medican survival compared with patients in group II (P = 0.001). Patients with cryptogenic cirrhosis were less likely to have undergone HCC surveillance and had larger tumors at diagnosis. In conclusion, hepatitis C and cryptogenic liver disease are the most common etiologies of diseases in our patients with HCC. NAFLD accounted for at least 13% of the cases. Patients who underwent surveillance had smaller tumors and were more likely to be candidates for surgical or local ablative therapies. Because of the increasing incidence of NAFLD, further studies are needed to determine the risk of HCC in patients with NAFLD. (Hepatology2002;36:1349-1354).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.1840360609

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 26

  1. Howe, 2001, Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends, J Natl Cancer Inst, 93, 824, 10.1093/jnci/93.11.824 · DOI · Paper page
  2. El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056/NEJM199903113401001 · DOI · Paper page
  3. Diehl, 1999, Nonalcoholic steatohepatitis, Semin Liver Dis, 19, 221, 10.1055/s-2007-1007111 · DOI · Paper page
  4. Bacon, 1994, Nonalcoholic steatohepatitis: an expanded clinical entity, Gastroenterology, 107, 1103, 10.1016/0016-5085(94)90235-6 · DOI · Paper page
  5. Caldwell, 1999, Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease, Hepatology, 29, 664, 10.1002/hep.510290347 · DOI · Paper page
  6. Poonawala, 2000, Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study, Hepatology, 32, 689, 10.1053/jhep.2000.17894 · DOI · Paper page
  7. Ong, 2001, Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver, Liver Transpl, 7, 797, 10.1053/jlts.2001.24644 · DOI · Paper page
  8. Bugianesi, 2002, Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma, Gastroenterology, 123, 134, 10.1053/gast.2002.34168 · DOI · Paper page
  9. El-Serag, 2001, Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States, Hepatology, 33, 62, 10.1053/jhep.2001.21041 · DOI · Paper page
  10. Oka, 1990, Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis, Hepatology, 12, 680, 10.1002/hep.1840120411 · DOI · Paper page
  11. Colombo, 1991, Hepatocellular carcinoma in Italian patients with cirrhosis, N Engl J Med, 325, 675, 10.1056/NEJM199109053251002 · DOI · Paper page
  12. Pateron, 1994, Prospective study of screening of hepatocellular carcinoma in caucasian patients with cirrhosis, J Hepatol, 20, 65, 10.1016/S0168-8278(05)80468-4 · DOI · Paper page
  13. Bolondi, 2001, Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis, Gut, 48, 251, 10.1136/gut.48.2.251 · DOI · Paper page
  14. Llovet, 1999, Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002/hep.510290145 · DOI · Paper page
  15. Alberti, 1998, Definition, diagnosis, classification of diabetes mellitus, and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
  16. Mazzaferro, 1996, Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104 · DOI · Paper page
  17. Brunt, 2001, Non-alcoholic steatohepatitis: definitions and pathology, Semin Liver Dis, 21, 3, 10.1055/s-2001-12925 · DOI · Paper page
  18. Younossi, 1998, Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations, Mod Pathol, 11, 560
  19. Zen, 2001, Hepatocellular carcinoma arising in non-alcoholic steatohepatitis, Pathol Int, 51, 127, 10.1046/j.1440-1827.2001.01174.x · DOI · Paper page
  20. Agarwal, 2001, Clinical, biochemical and histological profile of nonalcoholic steatohepatitis, Indian J Gastroenterol, 20, 183
  21. Yang, 2002, Hepatitis B antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056/NEJMoa013215 · DOI · Paper page
  22. Di Bisceglie, 1997, Hepatitis C and hepatocellular carcinoma, Hepatology, 26, 34S, 10.1002/hep.510260706 · DOI · Paper page
  23. Yuen, 2000, Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience, Hepatology, 31, 330, 10.1002/hep.510310211 · DOI · Paper page
  24. Llovet, 2000, Early diagnosis and treatment of hepatocellular carcinoma, Baillieres Clin Gastroenterol, 14, 991, 10.1053/bega.2000.0143 · doi:10.1053/bega.2000.0143
  25. Collier, 1998, Screening for hepatocellular carcinoma, Hepatology, 27, 273, 10.1002/hep.510270140 · DOI · Paper page
  26. Marrero, 2001, Des-γ carboxy prothrombin is a more sensitive and reliable marker for hepatocellular carcinoma than α-fetoprotein in american patients [Abstract], Hepatology, 34, 14A

Cited by

See all 660

Metadata

Authors
Marrero, J. A., Fontana, R. J., Su, G. L., Conjeevaram, H. S., Emick, D. M., & Lok, A. S.
Venue
Hepatology
Published
2002-12
Volume
36
Issue
6
Pages
1349-1354
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2052754205
Cited by
660
References
2
FWCI
15.47
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. https://app.cochat.ai/papers/10.1002/hep.1840360609
The paper
Marrero, J. A., Fontana, R. J., Su, G. L., Conjeevaram, H. S., Emick, D. M., & Lok, A. S. (2002). NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. Hepatology. https://doi.org/10.1002/hep.1840360609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.